REPLAGAL
SHP675-301
Approved small_molecule active
Quick answer
REPLAGAL for Fabry Disease is a Approved program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 5 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Fabry Disease
- Phase
- Approved
- Modality
- small_molecule
- Status
- active